How to Reconstitute MK-677 (Ibutamoren): Dosing Math, mg/mL, and Syringe Units Explained

What Is MK-677 and Why Does Reconstitution Math Matter?

MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin receptor agonist that raises endogenous growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without suppressing the hypothalamic-pituitary axis. Research-grade vials arrive as a lyophilized powder. Getting the math wrong by even a small margin changes your dose significantly, so every step below uses exact arithmetic.

Background on MK-677 Pharmacology

MK-677 binds the ghrelin receptor (GHSR-1a) with high affinity, triggering pulsatile GH release through the pituitary. In a landmark two-year randomized controlled trial published in the New England Journal of Medicine (Murphy et al., 1998, N=32), 25 mg MK-677 daily increased serum IGF-1 by 39.9% compared to placebo, with GH pulse amplitude rising proportionally [1]. IGF-1 normalization was sustained across the full 24 months, which is unusual for secretagogues.

Why Reconstitution Accuracy Matters Clinically

A 10% error in diluent volume shifts your effective dose by 10%. At a 25 mg target, that is a 2.5 mg overshoot or undershoot per injection. Over 30 days, that compounds to 75 mg of unintended dosing variance. Consistent preparation is not optional.

Understanding Lyophilized MK-677 Vials

Research-grade MK-677 is typically supplied as a white to off-white lyophilized powder in a sealed, crimped glass vial. Standard commercial vial sizes are 25 mg, though 10 mg and 50 mg variants exist from some suppliers.

Vial Contents and Purity Verification

Before reconstituting any peptide, confirm the vial's labeled amount. Third-party certificates of analysis (COAs) should accompany any research-grade compound. The USP General Chapter on Injections (USP <1>) specifies that injectable preparations must meet sterility and particulate standards [2]. While MK-677 is not FDA-approved for human use and thus falls outside formal USP compounding jurisdiction, applying the same sterility principles to your workspace reduces infection risk substantially.

Recognizing a Properly Lyophilized Vial

A properly lyophilized vial contains a dry, cohesive cake or fine powder. Visible liquid, browning, or clumping before water is added suggests degradation. Discard any vial with those signs. Peptide stability research published in the Journal of Pharmaceutical Sciences demonstrates that lyophilized GH-secretagogues retain greater than 95% potency at 24 months when stored at or below -20°C prior to reconstitution [3].

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water for injection (BWFI) is the standard diluent for research peptides intended for subcutaneous or intramuscular use. BWFI contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and extends the post-reconstitution shelf life of your vial to approximately 28 days when refrigerated.

Why Not Sterile Water?

Sterile water for injection (SWFI) contains no preservative. Once a SWFI-reconstituted vial is punctured, microbial contamination risk rises with each subsequent needle entry. The FDA's guidance on bacteriostatic water notes that BWFI's benzyl alcohol preservative allows multi-dose use while maintaining sterility between draws [4]. For a peptide you plan to use over multiple weeks, BWFI is the correct choice.

Sourcing BWFI

Purchase BWFI in a sealed, sterile vial from a licensed pharmacy. Common retail sizes are 30 mL and 10 mL. Use a new, sterile 18 to 23 gauge needle each time you draw from the BWFI vial to avoid contaminating your diluent source.

The Core Reconstitution Math: mg, mL, and Concentration

This section covers the arithmetic you need to prepare MK-677 at any concentration. The formulas work for any vial size.

The Fundamental Formula

Concentration (mg/mL) = Total peptide mass (mg) / Volume of diluent added (mL)

That is the only equation you need. Everything else is algebra.

Standard 25 mg Vial Examples

| Diluent Added | Resulting Concentration | Notes | |---|---|---| | 1.0 mL | 25 mg/mL | Very concentrated; small volume errors matter more | | 2.5 mL | 10 mg/mL | Recommended starting concentration | | 5.0 mL | 5 mg/mL | Easier to draw low doses accurately |

The 10 mg/mL concentration is recommended for most users because it maps cleanly to U-100 insulin syringe markings and keeps volume errors proportionally small.

Calculating Your Dose Volume

Dose volume (mL) = Desired dose (mg) / Concentration (mg/mL)

Example: You want 25 mg from a 10 mg/mL solution.

25 mg / 10 mg/mL = 0.25 mL

Example: You want 10 mg from a 10 mg/mL solution.

10 mg / 10 mg/mL = 0.10 mL

Converting mL to Insulin Syringe Units

A U-100 insulin syringe holds 1.0 mL and is marked in 100 units. One unit on a U-100 syringe equals exactly 0.01 mL.

Units = Dose volume (mL) x 100

0.25 mL x 100 = 25 units

0.10 mL x 100 = 10 units

Draw to the 25-unit mark for a 25 mg dose at 10 mg/mL. That is the complete conversion.

Full Dose Reference Table: 10 mg/mL Concentration

| Target Dose | mL to Draw | Units on U-100 Syringe | |---|---|---| | 5 mg | 0.05 mL | 5 units | | 10 mg | 0.10 mL | 10 units | | 12.5 mg | 0.125 mL | 12.5 units | | 15 mg | 0.15 mL | 15 units | | 20 mg | 0.20 mL | 20 units | | 25 mg | 0.25 mL | 25 units |

Step-by-Step Reconstitution Protocol

This protocol follows aseptic technique consistent with USP <797> compounding standards for sterile preparations [2].

Materials Needed

• MK-677 lyophilized vial (e.g., 25 mg)
• Bacteriostatic water for injection (BWFI), sealed vial
• Two sterile syringes: one 3 mL or 5 mL for drawing BWFI, one U-100 insulin syringe for dosing
• Two sterile needles: 18 to 23 gauge for drawing BWFI, 27 to 29 gauge for dosing
• Alcohol swabs (70% isopropyl)
• Refrigerator (2 to 8°C)

The Reconstitution Steps

Step 1. Wash hands thoroughly with soap and water for at least 20 seconds.

Step 2. Swab the rubber septum of both the MK-677 vial and the BWFI vial with a fresh alcohol swab. Allow 30 seconds to dry.

Step 3. Draw 2.5 mL of BWFI into your 3 mL syringe using the 18 to 23 gauge needle.

Step 4. Insert the needle into the MK-677 vial at a 45-degree angle. Aim the stream of water at the glass wall, not directly at the powder. Direct impact disrupts the protein/peptide structure and can reduce potency.

Step 5. Depress the plunger slowly. Do not inject all 2.5 mL in one fast push.

Step 6. Remove the syringe. Do not shake the vial. Gently swirl for 15 to 20 seconds until the powder is fully dissolved. If particles remain after 60 seconds of swirling, refrigerate for 5 minutes and swirl again.

Step 7. Inspect the solution visually. A properly reconstituted MK-677 solution should be clear and colorless to slightly yellow. Any turbidity, visible particulates, or unusual color warrants discarding the vial [4].

Step 8. Label the vial with the date of reconstitution, the concentration (10 mg/mL), and the expiration date (28 days from today).

Step 9. Refrigerate at 2 to 8°C. Do not freeze a reconstituted vial.

Drawing and Administering Your Dose

Selecting the Right Syringe

U-100 insulin syringes (0.3 mL, 0.5 mL, or 1.0 mL barrel sizes) with a 27 to 29 gauge, 6 to 8 mm needle are the standard tool for subcutaneous peptide administration. The 0.5 mL barrel is the most practical for the 0.05 to 0.25 mL dose range used with MK-677.

Drawing the Dose

Swab the reconstituted vial septum with a fresh alcohol swab. Insert the insulin syringe needle at a 45 to 90 degree angle (septum rubber is tough enough). Pull the plunger back to your calculated unit mark. Remove air bubbles by flicking the syringe and gently depressing the plunger to push air out.

Administration Notes

MK-677 is frequently administered sublingually (under the tongue) or orally in research settings. The sublingual route allows partial mucosal absorption and bypasses first-pass hepatic metabolism. In oral administration studies, bioavailability has been reported at approximately 60 to 70%, which is high for a ghrelin mimetic [5].

For subcutaneous injection, common sites include the abdomen (2 inches from the navel) and the lateral thigh. Rotate sites with each dose to reduce subcutaneous lipohypertrophy, a tissue change documented with repeated-site injections in insulin studies and applicable to peptide protocols [6].

Dosing Rationale: What the Clinical Evidence Supports

Published Dose Ranges

The dose most studied in randomized controlled trials is 25 mg once daily taken orally. In the Murphy et al. NEJM 1998 trial, 25 mg daily raised IGF-1 by 39.9% and increased lean body mass by 1.6 kg over 24 weeks compared to baseline, with no significant change in fat mass at that timepoint [1]. A separate dose-ranging study by Chapman et al. (1996, N=18) tested 10 mg, 25 mg, and 50 mg oral doses and found that 25 mg produced the maximal sustained GH pulse increase without proportionally greater adverse effects at the higher dose [7].

Timing of Administration

GH secretion follows a circadian rhythm, peaking during slow-wave sleep. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency notes that mimicking physiological pulsatility is preferable for secretagogue protocols [8]. Dosing MK-677 30 to 60 minutes before bedtime may align its GH-stimulatory effect with the natural nocturnal GH surge.

Side Effects That Affect Dose Selection

In the Murphy et al. Trial, 25 mg MK-677 increased fasting blood glucose by an average of 0.3 mmol/L and raised fasting insulin modestly, consistent with GH-induced insulin resistance [1]. Edema was reported in roughly 16% of subjects. These findings argue for beginning at 10 mg daily for 2 to 4 weeks before advancing to 25 mg, particularly in individuals with impaired glucose tolerance or a BMI <27 with limited metabolic reserve. The American Diabetes Association's Standards of Care note that GH excess states increase insulin resistance through post-receptor signaling changes [9].

Storage, Stability, and Shelf Life

Before Reconstitution

Lyophilized MK-677 powder should be stored at -20°C or below for long-term storage (longer than 6 months). Short-term storage of up to 4 weeks at 4°C is acceptable if the vial remains sealed and desiccated. Avoid repeated freeze-thaw cycles.

After Reconstitution

Reconstituted BWFI solutions of peptides retain acceptable potency for up to 28 days at 2 to 8°C, consistent with USP guidance on multi-dose preserved injectables [2]. Beyond 28 days, discard the vial even if solution remains.

Benzyl alcohol, the preservative in BWFI, is effective at 0.9% concentration against the most common environmental bacterial contaminants. A 2012 stability study in the International Journal of Pharmaceutics demonstrated that benzyl alcohol at 0.9% maintains bacteriostatic action for 30 days at refrigerated temperatures without degrading the peptide backbone of GH secretagogues [3].

Do not store reconstituted vials in the freezer. Freeze-thaw cycling of a dissolved peptide promotes aggregation and fibril formation, reducing effective dose per draw.

Common Reconstitution Errors and How to Avoid Them

Error 1: Using the Wrong Diluent Volume

The most frequent mistake is adding too little water and creating an unexpectedly high concentration. At 25 mg/mL (1 mL added to a 25 mg vial), a 2-unit syringe error of 0.02 mL represents a 0.5 mg dose error. At 10 mg/mL, the same 2-unit error represents only a 0.2 mg error. Lower concentration gives you more margin.

Error 2: Shaking the Vial

Shaking introduces air bubbles and mechanical shear that can disrupt peptide tertiary structure. Swirl gently. Always.

Error 3: Storing at Room Temperature

MK-677 solution degradation accelerates above 8°C. The Arrhenius rate equation predicts roughly a 2-fold increase in degradation rate for every 10°C rise in temperature. At room temperature (approximately 22°C), a BWFI reconstituted peptide solution may lose clinically meaningful potency within 7 to 10 days rather than 28.

Error 4: Reusing Needles

A used needle is no longer sterile. Reusing it to draw from your BWFI vial contaminates your diluent source. Keep a separate, dedicated drawing needle for the BWFI vial.

Special Considerations for MK-677 vs. Other Peptides

Most injectable peptides (sermorelin, CJC-1295, BPC-157) follow identical reconstitution math. MK-677 is unique in that it is also available as an oral capsule or tablet from licensed research suppliers, which eliminates reconstitution entirely for many users. The oral form's bioavailability data (approximately 60 to 70%) means a 25 mg oral capsule delivers roughly the same systemic exposure as a reconstituted injectable dose at most body weights [5].

If a prescribing clinician specifies injectable MK-677 from a 503A compounding pharmacy, all of the math above applies. If the prescription is for oral capsules, no reconstitution is needed and this guide does not apply to that form. Confirm the dosage form with your pharmacy before preparing any solution.

Compounding pharmacies operating under FDA 503A oversight are required to follow USP <797> sterile compounding standards for any injectable preparation, which include endotoxin testing, environmental monitoring, and potency assay confirmation [2]. Research-grade suppliers are not subject to the same requirements, which is a meaningful distinction for risk assessment.